Novavax, Inc.  

(Public, NASDAQ:NVAX)   Watch this stock  
Find more results for NVAX
10.41
-0.52 (-4.76%)
After Hours: 10.39 -0.02 (-0.19%)
Sep 3, 5:56PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.38 - 11.15
52 week 3.92 - 15.01
Open 11.03
Vol / Avg. 3.33M/5.64M
Mkt cap 2.94B
P/E     -
Div/yield     -
EPS -0.39
Shares 269.64M
Beta 1.11
Inst. own 70%
Nov 3, 2015
Q3 2015 Novavax Inc Earnings Release (Estimated) Add to calendar
Sep 9, 2015
Novavax Inc at FBR Healthcare Conference Add to calendar
Aug 12, 2015
Novavax Inc at Wedbush PacGrow Healthcare Conference
Aug 10, 2015
Q2 2015 Novavax Inc Earnings Call - Webcast
Aug 10, 2015
Q2 2015 Novavax Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -147.48% -270.55%
Operating margin -148.76% -272.97%
EBITD margin - -255.03%
Return on average assets -19.17% -32.46%
Return on average equity -21.03% -38.33%
Employees 308 -
CDP Score - -

Address

20 Firstfield Rd
GAITHERSBURG, MD 20878-1760
United States - Map
+1-240-2682000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Novavax, Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases, including Middle East respiratory syndrome (MERS).

Officers and directors

James F. Young Ph.D. Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Stanley C. Erck President, Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Barclay A. Phillips Chief Financial Officer, Senior Vice President, Treasurer
Age: 52
Bio & Compensation  - Reuters
Gregory M. Glenn M.D. Senior Vice President - Research & Development
Age: 61
Bio & Compensation  - Reuters
Timothy J. Hahn Ph.D. Senior Vice President - Manufacturing and Process Development
Age: 51
Bio & Compensation  - Reuters
John J. Trizzino Senior Vice President - Commercial Operations
Age: 55
Bio & Compensation  - Reuters
Russell P. Wilson J.D. Senior Vice President - Business Development
Age: 55
Bio & Compensation  - Reuters
Chris Dunne Vice President - Finance
Bio & Compensation  - Reuters
D. Nigel Thomas Vice President - Clinical Operations
Bio & Compensation  - Reuters
Gail Koziara Boudreaux Director
Age: 54
Bio & Compensation  - Reuters